July 2 2020

In the face of canceled medical meetings this spring, continuing medical education offerings from Physicians’ Education Resource, LLC® were quickly transitioned from an in-person format to virtual presentations that have the ability to reach more medical specialists nationwide.

Like never before, presentations related to systemic therapies for biliary tract cancers are taking center stage at medical and oncology conferences, generating hope that treating physicians will have multiple options in the near future.

A survey by MJH Life Science reveals how patient communication has evolved across clinical practices in the wake of COVID-19.

The efficacy of each combination therapy targeting KRAS will likely depend on the tumor lineage, said Gordon Mills, MD, PhD.

“In both subgroups, the benefit of veliparib was durable, with an increased probability of remaining progression free at 2 and 3 years compared with placebo,”

A pathogenic germline mutation rate of about 5% has been identified in women who had a family history of breast or ovarian cancer but no personal history of either disease.

Even as the United States slowly opens back up with restrictions on nonessential businesses easing, coronavirus disease 2019 has left an indelible mark on human history.

Exciting new knowledge and a more exquisite understanding of the role of tumor cell biology and the tumor microenvironment have driven the fields of precision oncology/genomics-based medicine and immuno-oncology/cancer immunotherapy.

Agents developed to prevent myelosuppression are the latest chemoprotectants under investigation in the treatment of various solid tumor malignancies.